Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma

Overview of attention for article published in Frontiers in oncology, August 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (55th percentile)
High Attention Score compared to outputs of the same age and source (82nd percentile)

So far, Altmetric has seen 8 X posts from 7 X users, with an upper bound of 39,975 followers.

RT @hjoan23: 📝 Publicació a @FrontOncology 🔬 Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carc…

RT @hjoan23: 📝 Publicació a @FrontOncology 🔬 Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carc…

RT @hjoan23: 📝 Publicació a @FrontOncology 🔬 Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carc…

📝 Publicació a @FrontOncology 🔬 Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma. 🔓 #openaccess #openscience 🌍 https://t.co/J85SFRF1Px #hjoan23publica #bibliohj23 https://t.co/WFBb0QHZUu

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 4 additional X posts.